ALK and non-small cell lung carcinoma: An example of treatment recommendations for advanced or metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangement positive is the use of anaplastic lymphoma kinase inhibitor drugs, as recommended by the National Comprehensive Cancer Network guideline 2021.8 However, the local cancer reimbursement protocol 2015 in Thailand recommends platinum (cisplatin or carboplatin) with paclitaxel, vinorelbine, docetaxel, gemcitabine or pemetrexed instead.9